A randomized, open label, two treatment, two period, two sequence, multiple-dose, crossover, full replicate, steady state, multicenter bioequivalence study of Aripiprazole for Extended-Release Injectable Suspension, 400 mg manufactured by Teva Pharmaceutical Industries Ltd., Israel compared to Abilify Maintena (aripiprazole) 400 mg Powder and Solvent for Prolonged-Release Suspension for Injection of Otsuka Pharmaceuticals, Netherlands in patients with schizophrenia under fasting condition

PLIVA Croatia Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1. Male or non-pregnant, non-lactating female subjects more than 18 and less than 63 years of age. 2. Patient with Body Mass Index between 18.5 and 35 kg/m2 3. Patient and patient’s legally acceptable representative (LAR) must demonstrate adequate decision-making ability to make an informed decision about participating in this study by providing written informed consent. 4. Patient with documented diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders – 5th edition (DSM-V) or latest version criteria. 5. Patient who is clinically stable and had no hospitalization for exacerbation of psychiatric symptoms in last 3 months before screening till randomization. 6. Patient who is currently stable on a regimen consisting of Aripiprazole prolonged/extended release injectable suspension every four weeks for at least 16 weeks (at least 4 doses) as judged by investigator prior to randomization. (Treatment phase criteria) 7. Adequate hematological, hepatic and renal parameters at screening and randomization. 8. Patients with Clinical Global Impression – Severity of illness (CGI-S) score of less than 5.

•1. Known or suspected allergy or hypersensitivity to aripiprazole or other constituents of the formulation. 2. Patients who are on active treatment with drugs that are known to be inducer or inhibitor of CYP3A4 and CYP2D6 enzymes and interact with Aripiprazole (see list of allowed and prohibited medications provided as separate Appendix II) 3. Subjects with history or at risk of venous thromboembolism as per investigator’s discretion. 4. Have a history of alcohol or drug-dependence during the 6-month period immediately prior to screening. 5. Subjects with a history of Neuroleptic Malignant Syndrome (NMS) or tardive dyskinesia while on treatment with atypical antipsychotics. 6. Subjects with dementia related psychosis. 7. Subjects with history or presence of seizures or other conditions that potentially lower the seizure threshold. 8. Patient with history or presence of pathological gambling and compulsive behavior.

发起方